Faga Daniel, PRES, CEO, reported an open-market or private sale at ANAPTYSBIO, INC involving 9202.000000 shares for an estimated $415102.22. Reported holdings after the transaction were 466787.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
President, CEO
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax…
The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of…
0 other filings
0 recent txs